Ãëàâíàÿ    Ex Libris    Êíèãè    Æóðíàëû    Ñòàòüè    Ñåðèè    Êàòàëîã    Wanted    Çàãðóçêà    ÕóäËèò    Ñïðàâêà    Ïîèñê ïî èíäåêñàì    Ïîèñê    Ôîðóì   
blank
Àâòîðèçàöèÿ

       
blank
Ïîèñê ïî óêàçàòåëÿì

blank
blank
blank
Êðàñîòà
blank
Gomperts B.D., Tatham P.E.R., Kramer I.M. — Signal Transduction
Gomperts B.D., Tatham P.E.R., Kramer I.M. — Signal Transduction



Îáñóäèòå êíèãó íà íàó÷íîì ôîðóìå



Íàøëè îïå÷àòêó?
Âûäåëèòå åå ìûøêîé è íàæìèòå Ctrl+Enter


Íàçâàíèå: Signal Transduction

Àâòîðû: Gomperts B.D., Tatham P.E.R., Kramer I.M.

Àííîòàöèÿ:

Signal Transduction is a text reference on cellular signalling processes. Starting with the basics, it explains how cells respond to external cues (hormones, cytokines, neurotransmitters, adhesion molecules, extracellular matrix, etc), and shows how these inputs are integrated and co-ordinated. The first half of the book provides the conceptual framework, explaining the formation and action of second messengers, particulary cyclic nucleotides and calcium, and the mediation of signal pathways by GTP-binding proteins. The remaining chapters deal with the formation of complex signalling cascades employed by cytokines and adhesion molecules, starting at the membrane and ending in the nucleus, there to regulate gene transcription. In this context, growth is an important potential outcome and this has relevance to the cellular transformations that underlie cancer. The book ends with a description at the molecular level of how signalling proteins interact with their environment and with each other through their structural domains. Each main topic is introduced with a historical essay, detailing the sources key observations and experiments that set the scence for recent and current work.


ßçûê: en

Ðóáðèêà: Òåõíîëîãèÿ/

Ñòàòóñ ïðåäìåòíîãî óêàçàòåëÿ: Ãîòîâ óêàçàòåëü ñ íîìåðàìè ñòðàíèö

ed2k: ed2k stats

Ãîä èçäàíèÿ: 2002

Êîëè÷åñòâî ñòðàíèö: 424

Äîáàâëåíà â êàòàëîã: 21.12.2005

Îïåðàöèè: Ïîëîæèòü íà ïîëêó | Ñêîïèðîâàòü ññûëêó äëÿ ôîðóìà | Ñêîïèðîâàòü ID
blank
Ïðåäìåòíûé óêàçàòåëü
$Ca^{2+}$      145—168 171—185
$Ca^{2+}$ ionophores      150
$Ca^{2+}$, adenylyl cyclase regulation      109 112 115
$Ca^{2+}$, bound      148—149
$Ca^{2+}$, complex formation      147—148
$Ca^{2+}$, cytosolic levels      149—166
$Ca^{2+}$, cytosolic levels, detection of changes      150—153 152 261
$Ca^{2+}$, cytosolic levels, elevation effects      172—173
$Ca^{2+}$, cytosolic levels, elevation mechanisms      153—162
$Ca^{2+}$, cytosolic levels, patterns of change in single cells      162—166 163 164 165
$Ca^{2+}$, electrically excitable cells      165—166
$Ca^{2+}$, free      148—149 148
$Ca^{2+}$, homeostasis      149
$Ca^{2+}$, intracellular localization      166—168
$Ca^{2+}$, intracellular localization, eukaryotic cell compartmentalization      146—147
$Ca^{2+}$, muscle contraction      165 166 182—185
$Ca^{2+}$, neurotransmitter secretion triggering      181—182
$Ca^{2+}$, PKC activation      199 200
$Ca^{2+}$, second messenger function      25 145—147 275
$Ca^{2+}$, trapped      148
$Ca^{2+}$, visual transduction      127 130
$Ca^{2+}$, visual transduction, negative regulation      135-137
$Ca^{2+}$-ATPase      149
$Ca^{2+}$-binding proteins      136 149 171—172 772
$Ca^{2+}$-binding proteins, polypeptide modules      401—403
$Ca^{2+}$-calmodulin-dependent protein kinase II      see "CaM-kinase II"
$Ca^{2+}$-calmodulin-sensitive adenylyl cyclase/phosphodiesterase      176—177
$Ca^{2+}$-dependent adhesion molecules      320
$Ca^{2+}$-dependent enzymes      172 178—180
$Ca^{2+}$-induced $Ca^{2+}$ release      see "CICR"
$Ca^{2+}$-sensing receptors      56—57
$Ca^{2+}$-sensitive photoproteins      150—151
$Fc\gamma$ receptor      215 316—317
$INF\alpha$-receptor      291 292
$Mg^{2+}$      147—148
$Mg^{2+}$, free      148 149
$P120^{GAP}$      see “Ras-GAP”
$P15^{INK4B}$      241 249 370
$P16^{INK4A}$      241 249
$P18^{INK4C}$      241
$P19^{INK4D}$      241
$P21^{WAFI/CIPI}$      211 241 242 246 330 370
$P27^{KIPI1}$      241 242 246
$P47^{gag-crk}$      262—263 263
$P47^{phox}$      215
$P57^{KIPI2}$      241 246
$P67^{phox}$      215 216
$P67^{phox}$, phosphorylation      215—217
$P67^{SRF}$      271
$P67^{TCF}$      271
$PLC\beta$      75 121 122 123 124
$PLC\beta$, G-protein $\alpha%-subunit activation      80
$PLC\beta$, G-protein-coupled activation      123—124
$PLC\delta$      121—122 123 124
$PLC\gamma$      121 122 123 124
$PLC\gamma$, activation      124—125 261
$PLC\gamma$, T cell activation      285 287
$pp60^{src}$      294
$TGF\alpha$      231
$TGF\beta$      19 20 231 232
$TGF\beta$ family      359—364 360
$TGF\beta$ receptors      359—362
$TGF\beta$, $TGF\beta1$-mediated activation      362 364 364
$TGF\beta$, accessory      362 363
$TGF\beta$, overexpression      368—369
$TGF\beta$, Smads regulation      366 367
$TGF\beta$, type I ($T\betaR-I$)      359 360—361 360 361 369
$TGF\beta$, type II (T\beta R-II)      359 360 361 369
$TGF\beta$, type III      362 363
$TGF\beta1$      359 362 363
$TGF\beta1$, $TGF\beta$ receptor activation      362 364 364
$TNF\alpha$ (tumour necrosis factoru)      23 348—349
$TNF\alpha$ receptor signalling complex      349 350
$TNF\alpha$, endothelial cell adhesion molecule regulation      349—351
$TNF\beta$ (tumour necrosis factor$\beta$)      349
$T\betaR-I$      359 360—361 360 361 369
$T\betaR-II$      359 360 361 361 369
$\alpha$-actinin      180
$\alpha$-adrenergic receptors      34 34 107 194
$\alpha$-adrenergic receptors, subtypes      35 35
$\alpha$-bungarotoxin      43—44
$\alpha$-type mating factor      3 96
$\beta$-adrenergic receptors      34 34 52 107 185 196
$\beta$-adrenergic receptors, adenylyl cyclase activation      63 75 191
$\beta$-adrenergic receptors, antagonists ($\beta$-blockers)      35 36 55 60
$\beta$-adrenergic receptors, dimerization      61 62
$\beta$-adrenergic receptors, inverse agonists      60
$\beta$-adrenergic receptors, overexpression      60
$\beta$-adrenergic receptors, subtypes      35 35
$\beta$-adrenergic receptors, transduction system construction in Sf9 cells      98—99 99
$\beta$-Catenin      249 333 334
$\beta$-catenin, mutations in cancer      334 334
$\beta$-Endorphin      4
$\beta$ARK ($\beta$-adrenergic receptor kinase)      84 85 197 276—277 278
$\gamma$-Aminobutyric acid      see “GABA”
11-cis-retinal      130 132 733
11-cis-retinal, light-induced isomerization      137 738
11-cis-retinal, rhodopsin interaction      54
3-phosphoinositide dependent protein kinase-1      see “PDK1”
5-hydroxytryptamine      see “Serotonin”
7TM receptors      38 40 51—58 see
7TM receptors, binding to low molecular mass ligands      55
7TM receptors, calcium sensors      56—57
7TM receptors, categories      52 54—55 54
7TM receptors, ERK activation      276—279
7TM receptors, G-protein linkage      72 73 99
7TM receptors, intracellular domains      65—66
7TM receptors, ligand binding sites      57
7TM receptors, metabotropic      42 56—57
7TM receptors, signal transmission      65—66
a-type mating factor      3 96
A2387      150
Abelson murine leukaemia virus      see "v-Abl"
Acetylcholine      11 14 38—39
Acetylcholine (cholinergic) receptors      38—42
Acetylcholine, cholinergic receptor interactions      40 42
Acetylcholine, cholinergic receptor interactions, muscarinic receptors      55
Acetylcholine, cholinergic receptor interactions, nicotinic receptors      44 49
Acetylcholine, neuromuscular junction actions      24
Acetylcholinesterase      38
Acetylcholinesterase inhibitors      39 39
ACTH (adrenocorticotrophic hormone)      4 20
ACTH, adenylyl cyclase activation      62 64—65 65
ACTH, receptor binding      55
Actin      182 325 329 332
Activator protein complex-1      see "AP-1"
Adenine      62 63
Adenosine receptor      63
Adenosine receptor, homodimers      62
Adenosis poliposis coli      see "APC"
Adenylyl cyclase      55 62—63 63 107—119
Adenylyl cyclase, $Ca^{2+}$-calmodulin-sensitive      176—177
Adenylyl cyclase, activation by receptors      62—63 63 64
Adenylyl cyclase, activation by receptors, experimental approaches      63-65 65
Adenylyl cyclase, ATP conversion to cAMP      72 109 109 110
Adenylyl cyclase, constitutive activity      59
Adenylyl cyclase, G-protein $\alpha$-subunit interactions      80 96 109 110 112 113 113
Adenylyl cyclase, G-protein $\beta\gamma$-subunit interactions      109 110 112 113—115 113
Adenylyl cyclase, GTP cofactor      72
Adenylyl cyclase, regulation      109—110 112—119 112 114
Adenylyl cyclase, structural organization      110—112 111
ADH (antidiuretic hormone)      see "Vasopressin"
Adherens junctions      321—322 322 331—332
Adherens junctions, cell polarity maintenance      332 332
Adhesion molecules      212 249 315—325 316
Adhesion molecules, cell cycle regulation      328—330 330 331
Adhesion molecules, cell survival promotion      325—328 327
Adhesion molecules, leukocyte trafficking      345—355
Adhesion molecules, nomenclature      318
Adhesion molecules, T cell activation      285
Adhesion molecules, tumour suppression      331—334
ADP ribosylation      116—119 117
Adrenaline (epinephrine)      2 9 20 22 31 32 33 62 66
Adrenaline, actions      33—34
Adrenaline, adrenergic receptor interactions      29 36 38
Adrenaline, historical aspects      8 9—10
Adrenergic receptors      31 32 34—38 34
Adrenergic receptors, adrenaline interactions      29 36 38
Adrenergic receptors, agonists      35—36 35
Adrenergic receptors, antagonists      35 36 60
Adrenergic receptors, G-protein signalling      51 115
Adrenergic receptors, ligand structural features      36 37 38
Adrenergic receptors, membrane spanning sequences/topology      51 52 53
Adrenergic receptors, subtypes      35 35 36
Adrenocorticotrophic hormone      see "ACTH"
Aequorin      150—151
AGC protein kinases      310 311
Aggrecan      324
Agonists      59 60 76 77
AIF (apoptosis inducing factor)      340
All-trans-retinal      132 133 137 139
Aluminium fluoride, adenylyl cyclase regulation      115—116
Amino acid receptors      42
AMPA receptors      158
Anaphase      238
Anaphase promoting complex/cyclosome      see "APC/C"
Anergy      285
ANF (atrial natriuretic factor)      4 20
Angiogenesis      248—249
Angiogenic factors      248 249
Angiotensin      36
Annexins      171
Antagonists      59 60
Antidiuretic hormone (ADH)      see "Vasopressin"
AP-1 (activator protein complex-1)      208 265 272 288
Apaf (apoptotic protease activating factor)      338 339
APC (adenosis poliposis coli)      249 333
APC, mutations in cancer      334 334
APC/C (anaphase promoting complex/cyclosome)      238 240 244 245
Apoptosis      22 179 227 240 242 248 249 325 326 335—340
Apoptosis inducing factor      see "AlF"
Apoptosis, avoidance (rescue pathway)      325—328
Apoptosis, bcl-2      338—339 338
Apoptosis, caspases      335—338
Apoptosis, cell morphology      335 336
Apoptosis, cytochrome c      339—340 340
Apoptosis, Fas ligand      339 339
Apoptosis, JNK pathway      327—328 328
Apoptotic protease activating factor      see "Apaf"
Arachidonate      23 23 204
Arf      86
Arrestin      84 139 276
Aspirin      23 299
Atenolol      37
ATM      243
ATP      19 71—72
ATP, cyclic AMP formation      109 109 110
Atrial natriuretic factor      see "ANF"
Atropine      11 15 40
Avian erythroblastosis virus      229
Avian leukaemia viruses      225—226
B lymphocyte receptor      283
b558      215
B7      288
Bacteriorhodopsin      51 66
Bad (Bcl associated dimer)      326 339 340
Basophils      23 212 288
Bax      242 340
Bcl associated dimer      see "Bad"
Bcl-2      249 337 338—339 338
Bcl-XI      249
Betaglycan      362
Bid      340
Binding affinity      25 26
Binding affinity, measurement      26—27 28
Binding reactions      25—28
Binding site heterogeneity      26
Boss (bride-of-sevenless)      266 267
Bradykinin      23
Brevican      324
Bride-of-sevenless      see "Boss"
Btk (Bruton’s tyrosine kinase)      80 294
Bub2      244
Bubl      244 245
C-terminal Src kinase      see "Csk"
C2 domain      171 179 181 402—403 403
C3bi      316
CAD (caspase activated DNAase)      226
Cadherins      249 320—322 327 322 331 332
Cadherins, classification      322
Cadherins, contact inhibition      334
cADPr (cyclic ADP-ribose)      159 160 760
Caenorhabditis elegans, Smad homologues      366 368
Caenorhabditis elegans, TGF$\beta$ receptor homologues      361 364—365
Caenorhabditis elegans, vulval cell development      268—269 269
CAK (CDK activating kinase)      235 237
Calcineurin (PP2B)      177 177 190 384 386 387
Calcineurin, T cell proliferation regulation      388—390 389
Calmodulin      154 173—174 174 175 275 388
Calmodulin, adenylyl cyclase regulation      112
Calmodulin, glycogenolysis regulation      175 176
Calpain      179
Calreticulin      149
CaM-kinase II ($Ca^{2+}$-calmodulin-dependent protein kinase II)      156 175 275
CaM-kinases      174—175 184
Cancer      247
Cancer, definition      246—247
Cancer, genetic alterations      249—250 334 334
Cancer, malignancy-related alterations      248—249
Carbachol      39
Carbarmylcholine      see “Carbachol”
Cardiac muscle, $Ca^{2+}$ signalling      166 182 185
Cartilage link proteins      324—325
Caspase activated DNAase      see “CAD”
Caspase-3      328
Caspase-8      339
Caspase-9      326 339
Caspases, apoptosis      335—338
Caspases, cellular targets      336—337 337
Caspases, effector      335 337
Caspases, initiator      335 337
Caspases, regulation      338
Catecholamines      2 32 33 34 194
Catecholamines, 7TM receptors      38
Catecholamines, receptor binding      55 56
Catenins      322 332
CBP (CREB binding protein)      194—195
CC chemokines      351 351 352
CD28      288
CD3      285 286
CD4      285 286 290
CD44      324—325 324
CD45 (leukocyte common antigen)      286 376—377 377
CD8      285 286 290
Cdc20      238 244 245 246
Cdc25      95 108 238
Cdc42      310
Cdc53 (Cullin)      246
Cdhl      238 240 246
CDK inhibitors      240—242 241
CDK-activating kinase      see “CAK”
CDK1      237 238 243
CDK2      236 237 241 330 407
CDK4      235 236 240 241 330
CDK6      235 236 241
CDK7      235 407
CDKs (cyclin-dependent protein kinases)      234
CED genes      335
Cell culture, historical aspects      230—231 231
Cell cycle      232—246
1 2 3 4 5
blank
Ðåêëàìà
blank
blank
HR
@Mail.ru
       © Ýëåêòðîííàÿ áèáëèîòåêà ïîïå÷èòåëüñêîãî ñîâåòà ìåõìàòà ÌÃÓ, 2004-2024
Ýëåêòðîííàÿ áèáëèîòåêà ìåõìàòà ÌÃÓ | Valid HTML 4.01! | Valid CSS! Î ïðîåêòå